Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

Cortex COR gedumpt

52 Posts
Pagina: «« 1 2 3 »» | Laatste | Omlaag ↓
  2. [verwijderd] 22 februari 2007 20:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Ksm00225 schreef:

    voorlopig geen nieuws te vinden...
    Vond dit op Yahoo, van de Roth conferentie:

    CX717 update:

    -histo events ARE post mortem
    -the histo event is now clearly documented
    -submission to FDA will occur in mid-March
    -electron microscope shows tissue as CLEAN
    -final tox study will be finished by months end
    -"I think we will get the dose limit lifted"
    -"data is coming in firmly"
    -over time structural changes seen after chemicals (ie: formaldehyde) are added Cortex

    Online comment 2/22/07

    Cortex was surprisingly definitive in their presentation at Roth Capital yesterday: the cellular 'signal' which has hamstrung the CX717 program since last April is a post-mortem artifact--it only occurs in tissue which is being prepared with a formalin-based fixative. If the same target tissue is instead frozen, the cellular signal is not seen, even when examined via electron microscope. Even the FDA will find it near-impossible to object to a resumption of full-dosage ADHD trials when the signal of concern only occurs after death. CEO Roger Stoll said quite bluntly--"I think we'll be able to get the dose limitation lifted by the FDA." No hedging with anything like 'of course, the final decision will be up to the FDA...' Cortex will submit the full package to the FDA in mid-March, and we expect a 'go' decision from the FDA in May. It has been a long wait, but it appears that CX717, which has now been more thoroughly vetted than any other Phase II drug, is in fact safe, and will go back into ADHD, where the initial findings were so positive. It was also timely in that this occurred on the day that the FDA announced that all current ADHD drugs would have to include inserts detailing their safety risks. CX717 appears to have none of their side effect baggage. This will add to the program's lustre as a partnerhip candidate, in addition to the high-impact group, where a partnership is expected midyear. Cortex is now in a position to resume the upward trajectory that was so abruptly interrupted last April--which for those who lost track during the interim, had the share price over 5. We expect it back in--and perhaps above--that range during 2007.

    Sentiment : Strong Buy

    Weet niet wat ervan waar is, maar heb toch een plukkie opgepakt!
  5. forum rang 4 Nel 22 februari 2007 21:55

    • Nel

      Lid sinds: 04 apr 2004

      Laatste bezoek: 04 feb 2025

    • Aanbevelingen

      Ontvangen: 1416

      Gegeven: 219

    •    Aantal posts: 27.770

    quote:

    papaa schreef:

    ga met je mee,zie idd kansen ,news is onderweg.

    succes
    ben blij met de aankoop
  8. [verwijderd] 22 februari 2007 22:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    The Wishbone schreef:

    Plukje gekocht op 1.56

    Positief is ze hebben geld binnen gehaald op 27 januarie

    Partner is akzonobel

    We zullen het zien.

    Op Yahoo zijn ze in ieder geval erg positief!
  14. Smartie2000 22 februari 2007 23:38

    • Smartie2000

      Lid sinds: 07 feb 2006

      Laatste bezoek: 27 jul 2024

    • Aanbevelingen

      Ontvangen: 10

      Gegeven: 4

    •    Aantal posts: 158

    De toegelaten dosis van cx717 werd door de fda vorig jaar tot een max beperkt. Gevolg daling tot $1. Cox heeft nu gezegd dat hij zeker is dat deze beperking door de fda wordt opgeheven en dat koers weer naar de $5 zal stijgen.

    Cortex

    Online comment 2/22/07

    Cortex was surprisingly definitive in their presentation at Roth Capital yesterday: the cellular 'signal' which has hamstrung the CX717 program since last April is a post-mortem artifact--it only occurs in tissue which is being prepared with a formalin-based fixative. If the same target tissue is instead frozen, the cellular signal is not seen, even when examined via electron microscope. Even the FDA will find it near-impossible to object to a resumption of full-dosage ADHD trials when the signal of concern only occurs after death. CEO Roger Stoll said quite bluntly--"I think we'll be able to get the dose limitation lifted by the FDA." No hedging with anything like 'of course, the final decision will be up to the FDA...' Cortex will submit the full package to the FDA in mid-March, and we expect a 'go' decision from the FDA in May. It has been a long wait, but it appears that CX717, which has now been more thoroughly vetted than any other Phase II drug, is in fact safe, and will go back into ADHD, where the initial findings were so positive. It was also timely in that this occurred on the day that the FDA announced that all current ADHD drugs would have to include inserts detailing their safety risks. CX717 appears to have none of their side effect baggage. This will add to the program's lustre as a partnerhip candidate, in addition to the high-impact group, where a partnership is expected midyear. Cortex is now in a position to resume the upward trajectory that was so abruptly interrupted last April--which for those who lost track during the interim, had the share price over 5. We expect it back in--and perhaps above--that range during 2007.

    www.neuroinvestment.com/CORXcom.html

  15. [verwijderd] 23 februari 2007 05:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    After Hours
    Last: $ 1.75 After Hours
    High: $ 1.75
    After Hours
    Volume: 10,200 After Hours
    Low: $ 1.62

    After Hours
    Time (ET) After Hours
    Price After Hours
    Share Volume
    18:01 $ 1.69 100
    18:01 $ 1.69 100
    18:01 $ 1.69 300
    18:01 $ 1.75 1,400
    17:48 $ 1.64 100
    17:48 $ 1.67 500
    17:21 $ 1.64 100
    17:21 $ 1.64 400
    16:39 $ 1.62 900
    16:39 $ 1.62 3,600
    16:07 $ 1.64 100
    16:07 $ 1.64 300
    16:06 $ 1.64 100
    16:02 $ 1.62 2,200
  16. [verwijderd] 23 februari 2007 16:56

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Laatste koers Verschil

    1.87 USD 0.23 (14.02 %)
    Volume Tijdstip
    1976200 2007-02-23 16:53:52
    Slotkoers Openingskoers
    1.64 1.87
    Laagste v/d dag Hoogste v/d dag
    1.75 1.98


  19. [verwijderd] 23 februari 2007 19:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    "New information indicates that CX717 may be nontoxic," wrote analyst Elemer Piros, upgrading the stock to "Market Outperform" from "Market Perform" with a $4.50 price target.

    quote:

    skippy44 schreef:

    Ja het is hier windstil.Ook nog geen reactie op Cnlg.

    Laatste koers Verschil

    1.85 USD 0.21 (12.8 %)
  20. [verwijderd] 23 februari 2007 19:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    The Wishbone schreef:

    Iemand er nog in of hebben jullie al winst gepakt?

    Koers 1,89
    Ik zit er nog Wish! Gisteren fors ingestapt en heerlijk van de rit aan het genieten! Ik blijf voorlopig ook heerlijk zitten!

    succes!
52 Posts
Pagina: «« 1 2 3 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.192
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.501
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.648
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.884
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.991
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.035
Alfen 16 24.319
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.709
AMG 971 133.042
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 482
Antonov 22.632 153.605
Aperam 92 14.900
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.549
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.976
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.609
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390